Transition-Metal-Free Olefinic C–H Azidoalkylthiolation *via* C(*sp*³)–S Bond Cleavage of Vinylsulfonium Salts

Yuan He,^{a, b} Zilong Huang,^{a, b} Juan Ma,^{a, b} Jie Lin,^{a, b} Yong-Gui Zhou,^{a,*} and Zhengkun Yu^{a, c, d,*}

^a Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian, Liaoning 116023, People's Republic of China

E-mail: zkyu@dicp.ac.cn; ygzhou@dicp.ac.cn

^b University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China

^c Innovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing 100190, People's Republic of China

^d State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, People's Republic of China Fax: +86-411-8437-9227

Manuscript received: May 17, 2022; Revised manuscript received: July 15, 2022; Version of record online: August 9, 2022

Supporting information for this article is available on the WWW under https://doi.org/10.1002/adsc.202200529

Abstract: A transition-metal-free olefinic C–H azidoalkylthiolation protocol was developed through $C(sp^3)$ –S bond cleavage of vinylsulfonium salts with sodium azide in air under aqueous conditions. An interrupted Pummerer/nucleophilc azidoalkylation cascade was developed for such a process. The practicability of the synthetic protocol was demonstrated by scale-up preparation of the azidoalkylthiolated tetrasubstituted alkene products and their transformations to diverse triazole and tetrazole derivatives as well as azidoalkylthio-functionalized *N*-heterocyclic compounds. The present synthetic methodology features broad substrate scopes and good functional group tolerance under mild conditions.

Keywords: azidoalkylation; vinyl sulfonium salts; $C(sp^3)$ -H functionalization; sodium azide; $C(sp^3)$ -S cleavage

Introduction

Azido compounds are important intermediates in organic synthesis, and azido group (N_3) exists in some natural and synthetic functional materials. For example, alkylazido-substituted β -thymidines can act as anti-HIV drug^[1] and HCV inhibitor,^[2] and tazobactam with a thiazole structural motif which is generated from a N₃-containing compound (azide) has been used as a β -lactam antibiotic^[3] (Scheme 1). Owing to the potential importance of N₃-bearing compounds and their derivatives various methods have been developed for the synthesis of diverse organic azides and their transformations.^[4] Reactive azides usually serve as intermediates for a large number of transformations that afford amines, imines, amides, aziridines, triazoles, and other *N*-heterocycles.^[5,6] These conversions are either based on [3+2] cycloadditions,^[7] or Staudinger-type transformations.^[8] Moreover, organic azides are convenient nitrene precursors, featuring no need of external oxidant and release of N₂ as the only



Scheme 1. Representative biologically active alkyl azides and derivatives.

by-product.^[9a] In this context, development of sustainable methods for the establishment of $C(sp^3)$ —N₃ bonds is extremely desired not only in organic synthesis but also in drug discovery.

To access alkyl azides, three general methods have been developed: nucleophilic substitution, addition of an azido anion to electrophilic substrates and diazo transfer to primary amines with triflyl azide (Scheme 2a, left).^[6-8] Azidoalkylation can also be achieved

(a) Known azidoalkylation methods



Y = leaving group

(b) Azidoalkylation via alkyl sulfonium salts^[11a]



(c) This work: azidoalkylation via vinyl sulfonium salts



Scheme 2. Azidoalkylation strategies.

by means of azide compounds and specific radical sources.^[9b-h] However, the classic nucleophilic substitution and addition reactions usually require substrate prefunctionalization and/or harsh (elaborate) reaction conditions, which leads to the target products in low yields with narrow substrate scopes, poor functional group tolerance, long reaction time, and/or complicated work-up manipulations. In addition, these known methods still remain a significant challenge in their practical applications. Thus, there has been an urgent need to develop applicable synthetic methodologies of complex alkyl azides. Radical-initiated azidation of C-C multiple bonds provides a powerful approach for the synthesis of functionalized alkyl azides.^[10a] Regioselective introduction of an azido group through direct $C(sp^3)$ -H transformation avoids prefunctionalization of the substrates and offers a straightforward access to the desired scaffold in high atom and step-economy.^[10b] Cycloaddition, cyclization, and migration reactions of vinyl azides in which the azide functionality is kept in the final products are also potentially useful for the synthesis of alkyl azides which are difficult to be constructed by the conventional methods (Scheme 2a, right).^[10c] It has been known that S-alkyl tetrahydro-1H-thiophen-1-ium salts and analogs can undergo nucleophilic ring-opening reactions with nucleophiles such as azide, thiolates, halogens, amines.^[11] Unfortunately, in the case of azidoalkylation with sodium azide only three inefficient examples were reported (12-39% yields) through ring opening of the alkylsulfonium salts (Scheme 2b).[11a]

Arylsulfonium salts have been paid much attention as useful coupling partners^[12] not only in light of their accessibility from simple arenes but also due to their versatility for many $C-C^{[13]}$ and $C-X^{[14]}$ bond formation reactions. As two types of common arylsulfonoum salts, aryl thianthrenium salts and dibenzothiophene sulfonium salts have been successfully applied for siteselective late-stage diversification of C-N crosscouplings.^[14a,b] However, the analogs of aryl sulfonium salts, that is, vinylsulfonium salts, have been paid much less attention as applicable coupling partners.^[15] Very recently, Wen and coworkers realized the synthesis of alkyl amines via the $C(sp^3)$ -S bond cleavage of vinylsulfonium salts.^[15g] During the continuous exploration of the multiple reactivities of functionalized olefins,^[12b,16] we recently achieved palladiumcatalyzed C–H fluoroalkylthiolation through $C(sp^3)$ –S bond cleavage of vinylsulfonium salts with CsF.^[17] We thus envisioned the possible azidoalkylthiolation of vinylsulfonium salts using a similar strategy. Herein, we report an interrupted Pummerer/transition-metalfree azidoalkylation cascade for olefinic C-H azidoalkylthiolation via vinylsulfonium salts (Scheme 2c).

Results and Discussion

asc.wiley-vch.de

Initially, the reaction of 1-(1,1-bis(methylthio)-3-oxo-3-phenylprop-1-en-2-yl)tetrahydro-1*H*-thiophen-1-ium trifluoro-methanesulfonate (1a) and sodium azide (NaN₃) was conducted to screen the reaction conditions for the formation of 2-((4-azidobutyl)thio)-3,3bis(methylthio)-1-phenylprop-2-en-1-one (2a). Vinylsulfonium salt 1a and its analogs were efficiently prepared from the readily available alkenes by the well-known interrupted Pummerer reaction (see the SI for details). The reaction conditions for the synthesis of 2a (93%) were optimized to: molar ratio of 1a: $NaN_3 = 1:2$, $H_2O/EtOH$ (v/v = 1/1) as the solvent, 60°C, and 6 h under an air atmosphere (Table 1, entry 1). The reaction reached 73% yield for the target product under aqueous conditions, and use of an organic solvent such as ethanol increased the yield to 81% (Table 1, entries 2 and 3). It is noteworthy that addition of an organic solvent improved the solubility of substrate 1a in the reaction medium, which thus increased the product yields to 92-94% (Table 1, entries 1, 4, and 5). Although the MeOH/H₂O solvent system behaved a little bit better than EtOH/H₂O did, the latter was chosen as the reaction medium due to the lower toxicity of ethanol. Change of trifluoromethanesulfonate anion with tetrafluoroborate or hexafluorophosphate diminished the yields to 69-73% (Table 1, entries 6 and 7). The counterions exhibited an obvious impact on the reactivity of the sulfonium salt presumably due to the electronegativity of the oxygen atom in OTf⁻ anion greater than those of the central atoms in BF_4^- and PF_6^- anions. In our case, OTf^- anion is more



Table 1. Screening of reaction conditions.^[a]



^[a] Conditions: **1 a** (0.3 mmol), NaN₃ (0.6 mmol), solvent (2 mL), air, 6 h.

^[b] Determined by ¹H NMR analysis using 1,3,5-trimethoxylbenzene as the internal standard.

^[c] Isolated yield given in parentheses.

^[d] Using TMSN₃, p-TsN₃, or Ph₂P(O)N₃.

compatible with the alkenylsulfonium cation than other counterions. $60 \,^{\circ}\text{C}$ seemed to be the appropriate reaction temperature (Table 1, entries 8 and 9). Covalent azide sources, i.e., trimethylsilyl azide, *p*-tosyl azide, and diphenylphosphoryl azide, failed to undergo the azidoalkylation reaction (Table 1, entry 10). For manipulation simplicity, the reaction was conducted under an air atmosphere (Table 1, entries 11 and 12). It should be noted that vinyl azide 2a' was not detected in the reaction mixture under the stated conditions.

Next, the scope of vinylsulfonium salts 1 generated from di(alkylthio)-substituted alkenes, that is, ketene dithioacetals, was investigated under the optimal conditions (Table 2). This type of substrates showed moderate to excellent reactivity to form the target azidoalkylation products of type 2. On a 5 mmol scale of 1a product 2a was still obtained in 83% yield. Di(ethylthio) and ethylene disulfide group-substituted vinylsulfonium salts (1 b-1 c) also efficiently reacted with NaN₃ to give products 2b-2c (90–92%). However, cycloalkyldithio $S(CH_2)_3S$ -substituted α -benzoyl vinylsulfonium salt 1d only exhibited a moderate reactivity to generate 2d (42%). The yield of 2d is much lower than 2c, which is a result of the unidentified side reactions. An obvious steric effect was observed from *ortho*-methyl group on the α benzoyl moiety of vinylsulfonium 1 e, leading to 2 e in 58% yield, while 3- and 4-methyl-substituted ketene



^[a] Conditions: 1 (0.30 mmol), NaN₃ (0.60 mmol), H₂O/EtOH (v/v = 1/1, 2 mL), air, 60 °C, 6 h. Yields refer to the isolated products.

^[b] 1 (5.0 mmol), NaN₃ (10.0 mmol), H₂O/EtOH (v/v = 1/1, 20 mL).

3025

dithioacetals 1f and 1g efficiently reacted with NaN₃ to afford 2f (85%) and 2g (89%), respectively. Electron-withdrawing trifluoromethyl had an obvious negative impact on the reaction efficiency, resulting in **2h–2j** in 50–68% yields. 4-Halogen (F, Cl, and Br) functionalized vinylsulfonium salts 1k-1m also reacted well with NaN₃ to give 2k-2m (72–93%). The bulkiness of 2-naphthoyl did not affect generation of the target product (2n, 90%) either. It is noteworthy that α -heteroaroyl such as 2-furoyl or 2-thienoylsubstituted vinylsulfonium salts reacted well with NaN₃ to give **20** and **2p** in 91–94% yields. In a similar fashion, cycloalkyldithio-substituted vinylsulfonium salts, that is, α -benzoyl ketene dithioacetals 1 q - 1 u, underwent the same type of reaction to form the corresponding products 2q-2u (59-88%). The reactions of α -(2-naphthoyl) and α -acetyl-fuctionalized vinylsulfonium salts 1v and 1w with NaN₃ also smoothly proceeded to give 2v and 2w (71–81%).

In order to further probe into the C-S bond reactivity of vinylsulfonium salts, the substituent and size effects from the cycloalkylsulfonium ring were explored [Eq.s (1-2)]. The vinylsulfonium salts derived from 2-methyltetrahydro-1H-thiophene, that is, vinylsulfonium salts 3a and 3b, with NaN₃ gave a mixture of two inseparable azidoalkylation products 4a/5a (77%, 1.8:1) and 4b/5b (69%, 1.1:1) via different aliphatic C-S bond cleavages of the cycloalkylsulfonium ring [Eq. (1)], which reveals that the sterically hindered $C(sp^3)$ -S bond is easier to be cleaved. However, the corresponding vinylsulfonium salt of thietane $((CH_2)_3S)$ was decomposed quickly under the standard conditions. To our delight, the vinylsulfonium salts (6) of tetrahydro-2H-thiopyrans could efficiently react with NaN₃ to afford the target C₅-azidoalkylthio functionality-bearing products 7 a-7c (61-72%) [Eq. (2)]. Unfortunately, the vinylsulfonium salts derived from the large-ring aliphatic cyclic sulfoxides $C_nH_{2n}S=O$ (n ≥ 6) could not be successfully prepared by the known methods, we thus failed to further expand the azidoalkylthio chain. Vinyl thianthrenium and dibenzothiophenium salts were also tested under the standard conditions, which exhibited a negative steric/electronic effect to result in none of the target azidoalkylthiolation products.

The scope of other types of vinylsulfonium salts, that is, styryl sulfonium salts (8), was also investigated (Table 3). 1,1-Diphenyl-substituted vinylsulfonium salt 8a reacted with NaN₃ under the optimal conditions to give the target product 9a in 84% yield. A gram-scale preparation also efficiently produced compound 9a (78%). When two different aryls were installed at the same terminus of the vinyl moiety, a mixture of two isomeric azidoalkylation products were usually isolated. Thus, compounds 9b (64%, E/Z=3:1), 9d (77%, E/Z=1.8:1), 9e (71%, E/Z=1:1), and 9g (62%, E/Z=1.7:1) were obtained. It should be noted that in

 Table 3. Scope of styrylsulfonium salts (8).

asc.wiley-vch.de

Advanced

Catalysis

Synthesis &



^[a] Conditions: **8** (0.30 mmol), NaN₃ (0.60 mmol), H₂O/EtOH (v/v = 1/1, 2 mL), air, 60 °C, 6 h. Yields refer to the isolated products.

^[b] $\stackrel{1}{8}$ (5.0 mmol), NaN₃ (10.0 mmol), H₂O/EtOH (v/v=1/1, 20 mL).

^[c] The E/Z isomer ratio was determined from the isolated products by ¹H NMR analysis.

the cases of using unsymmetrical alkenylsulfonium salts the E/Z ratios of the isolated azidoalkylation products remain unchanged as compared to those of the starting sulfonium salts. It is notable that a steric

4dv.	Synth.	Catal.	2022,	364,	3023-3034	
------	--------	--------	-------	------	-----------	--



effect was observed from the ortho-methyl group, leading to 9b in 64% yield, while the negative steric effect could be compensated by the electronic effect of the *ortho*-bromo group to result in **9**c (87%) as a single (E)-isomer. In the cases of placing two same aryls at the same terminus of the vinyl moiety, single isomeric products 9f and 9h-9i (72-84%) were efficiently generated. 1,2-Diaryl-functionalized vinylsulfonium salts, that is, the sulfonium salts of 1,2-stilbenes, also reacted well with NaN₃ under the stated conditions, giving 9j-9m (51-75%). Compared to the formation of 9 i (51%) a positive substituent effect facilitated the production of 9 k/9 k' (61%) and 91 (75%). Compound 8k is a mixture of regionsomers which resulted in 9k/ $9 \mathbf{k}'$ as a mixture with the same regionsomer ratio. It is noteworthy that the monoaryl-functionalized sulfonium salt, that is, styrylsulfonium salt 8n, was readily decomposed under the stated conditions that the corresponding target product 9n was only formed in 38% yield. The low yield of **9n** is presumably attributed to the competitive nucleophilic attack of N₃⁻ anion at the β -position of the alkenylsulfonium salt.^[15h-j] An additional aryl at the vinyl moiety gives extra stabilization to the 1,1- and 1,2-diarylvinylsulfonium salts 8 a-8 m due to the conjugation effect, which renders them to react with NaN₃ more efficiently to afford the target products in decent yields. Unexpectedly, the sulfonium salt of 2-methylstyrene (80) seldomly underwent the same type of azidoalkylation reaction to form the corresponding product 90. Interestingly, the 1,1-diphenyl vinylsulfonium salt (8p) of six-membered cyclic tetrahydro-2H-thiopyran underwent the ring-opening azidoalkylation to afford the corresponding product 9p (77%) bearing a C₅azidoalkylthio chain.

The reactivities of open-chain vinylsulfonium salts was then comparatively investigated [Eq.s (3-4)]. Treatment of vinylsulfonium salt 10 a (R=Me) derived from 1,1-stilbene and dimethylsulfoxide (DMSO) with NaN₃ under the standard conditions gave both methylthiolated alkene 11 a (89%) and methyl azide. Sulfonium salts 10b–10d behaved in a fashion similar to form 11b-11d (43-78%) [Eq. (3)]. The vinylsulfonium salt of methyl phenyl thioether (12a) predominantly underwent the azidation through C-S cleavage of the S-C(methyl) bond to form 11d (43%) with formation of MeN₃. No PhSMe was detected from the reaction mixture by GC-MS analysis, suggesting that no S-C(phenyl) bond cleavage occurred in the reaction of 12 a with NaN₃. In the case of using the vinylsulfonium salt of methyl decyl thioether (12b), two kinds of $C(sp^3)$ -S bond cleavages proceeded to give 11e (25%) and 11a (51%) [Eq. (4)]. Notably, MeN₃ and decyl azide were detected by GC-MS analysis in the reaction mixtures, respectively (See the SI for details). In all the cases, no vinyl azides were detected as the side products. This type of reactions can be considered as an alternative method to access vinyl thioethers.

To investigate the applicability of the present synthetic protocol, the resultant azidoalkylthiolated alkene 2a was transformed under diverse reaction conditions (Scheme 3). Two transformable moieties, that is, azido and α -oxo ketene dithioacetal, exist in compounds of type 2. Organic azides have been found broad synthetic utilities in copper-catalyzed azidecycloaddition^[7] alkyne and Staudinger bioconjugation.^[8] A [3+2] cycloaddition reaction of 2 a with phenylacetylene was conducted to selectively afford vinylthioalkyl-functionalized triazole 13 in 91% yield (Scheme 3a). Further condensation of 13 with hydrazine gave thioalkyl-linked bis(N-heterocycle) 14 (40%) (Scheme 3b). Usually, such a bis(heterocycle) is difficult to be constructed by a conventional method.^[18] Vinylthioalkyl-functionalized tetrazole 15 (51%) was accessed from the reaction of 2a and benzoyl cyanide (Scheme 3c). Notably, the azido functionality could withstand various reaction conditions in the present work. In refluxing ethanol 2a reacted with hydrazine hydrate and phenylhydrazine to give azidoalkylthiofunctionalized multisubstituted pyrazoles 16 (87%) and 17 (72%) (Scheme 3d and 3e), respectively. In a similar fashion, isoxazole 18 (81%) was prepared by the condensation of 2a with hydroxylamine (Sche-Interestingly, azidoalkylthio-functionalized me 3f).



Scheme 3. Product derivatization. Reagents and conditions:^[a] Phenylacetylene (2 equiv.), CuBr (10 mol%), 1,4-dioxane (2 mL), air, 80 °C, 12 h.^[b] Hydrazine hydrate (10 equiv.), EtOH (2 mL), air, 80 °C, 12 h.^[c] Benzoyl cyanide (2 equiv.), MeCN (2 mL), air, 130 °C, 36 h.^[d] Hydrazine hydrate (10 equiv.), EtOH (2 mL), air, 80 °C, 12 h.^[e] Phenylhydrazine (2 equiv.), EtOH (2 mL), air, 80 °C, 24 h.^[f] Hydroxylamine hydrochloride (10 equiv.), K₂CO₃ (10 equiv.), EtOH (2 mL), air, 80 °C, 12 h.^[g] Guanidine nitrate (2 equiv.), K₂CO₃ (2 equiv.), MeCN (2 mL), air, 100 °C, 36 h.

Adv. Synth. Catal. 2022, 364, 3023-3034

Wiley Online Library 3027

pyrimidine 19 was also produced by the reaction with guanidine nitrate in 63% yield (Scheme 3g). It should be noted that the molecular structure of compound 17 was further confirmed by the X-ray single-crystal crystallographic determinations, verifying formation of the present N-heterocycle and establishment of the azidoalkylthio functionality in the C-H azidoalkylthiolation products (see the SI for details).

Control experiments were conducted to probe into the reaction mechanism. The reaction of 1 a with NaN₃ was carried out in the presence of 3.0 equiv. of 2,2,6,6tetramethyl-1-piperidinyloxy (TEMPO) or 2,6-di-tertbutyl-4-methylphenyl (BHT) under the standard conditions (see the SI for details). These radical-trapping reagents could not inhibit the ring-opening azidoalkylthiolation reaction, leading to 2 a in 78–85% yields, which excludes a radical pathway. We reasonably speculate that this reaction is a nucleophilic substitution process of azide anion (N_3^-) via aliphatic C-S bond cleavage of the cycloalkylsulfonium ring.

Conclusions

In conclusion, an olefinic C-H azidoalkylthiolation strategy was developed by means of an interrupted Pummerer/nucleophilc azidoalkylation cascade. Multisubstituted azidoalkylthiolated alkenes can be accessed through ring-opening azidoalkylation of vinylsulfonium salts under air conditions. The synthetic protocol has been shown potentials for the synthesis of diverse azidoalkylthiolated N-heterocycles.

Experimental Section

General Considerations

¹H and ¹³C{¹H} NMR spectra were recorded on a 400 MHz spectrometer and all chemical shift values refer to CDCl₃ $(\hat{\delta}(^{1}\text{H}), 7.26 \text{ ppm} \text{ and } \delta(^{13}\text{C}), 77.16 \text{ ppm})$. X-Ray crystallographic analysis was achieved by the Analysis Center, Dalian Institute of Chemical Physics, Chinese Academy of Sciences. The X-ray crystallographic files, in CIF format, are available from the Cambridge Crystallographic Data Centre on quoting the deposition numbers CCDC 2080911 for 17. Copies of this information may be obtained free of charge from The Director, CCDC, 12 Union Road, Cambridge CB2 IEZ, UK (Fax: +44-1223-336033; e-mail: deposit@ccdc.cam.ac.uk or www: http:// www. ccdc.cam.ac.uk). The HRMS analysis was obtained by ESI on a GC-TOF mass spectrometer. Column chromatographic purifications were performed on silica gel. All the chemical reagents were purchased from commercial sources and used as received unless otherwise indicated. NaN₃ is of great acute toxicity, which requires attention during experimental operation.

Typical Procedure for the Synthesis of Compounds (2) and (9) - Synthesis of 2 a

Advanced

Catalysis

Synthesis &

A mixture of 1-(1,1-bis(methylthio)-3-oxo-3-phenylprop-1-en-2-yl)tetrahydro-1H-thiophen-1-ium trifluoromethanesulfo-nate (1a) (138 mg, 0.3 mmol), NaN₃ (39 mg, 0.6 mmol), and 2 mL H₂O/EtOH (1/1, v/v) was stirred at 60 °C for 6 h under an air atmosphere. After 1a was completely consumed by TLC monitoring on silica gel, all the volatiles were evaporated under reduced pressure. The resultant residue was purified by silica gel column chromatography (eluent: petroleum ether (60-90 °C)/ethyl acetate = 30:1, v/v), affording **2a** (97 mg, 91%) as a yellow liquid.

2-((4-Azidobutyl)thio)-3,3-bis(methylthio)-1-phenylprop-2-

en-1-one (2 a): 90 mg, 85%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) & 8.00-7.84 (m, 2 H), 7.56 (m, 1 H), 7.51-7.43 (m, 2 H), 3.25-3.10 (m, 2 H), 2.60 (m, 2 H), 2.42 (s, 3 H), 2.06 (s, 3 H), 1.60 (m, 4 H). ${}^{13}C{}^{1}H$ NMR (100 MHz, CDCl₃) δ 191.1, 138.9, 135.9, 133.8, 132.8, 129.4, 128.8, 50.9, 33.0, 27.7, 26.7, 18.4, and 16.3. HRMS (ESI-TOF) m/z: $[M+H]^+$ Calcd for C₁₅H₂₀N₃OS₃ 354.0768; Found 354.0763.

2-((4-Azidobutyl)thio)-3,3-bis(ethylthio)-1-phenylprop-2-en-1-one (2 b): 103 mg, 90%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 8.03–7.91 (m, 2 H), 7.59 (s, 1 H), 7.47 (t, J=7.6 Hz, 2 H), 3.20 (s, 2 H), 2.93 (q, J=7.3 Hz, 2 H), 2.68-2.53 (m, 4 H), 1.62 (m, 4 H), 1.34 (t, J=7.3 Hz, 3 H), 1.01 (t, J=7.4 Hz, 3 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 191.6, 141.4, 136.0, 133.8, 130.1, 129.6, 128.9, 51.0, 32.9, 29.2, 27.8, 27.7, 26.7, 15.3, and 14.4. HRMS (ESI-TOF) m/z: $[M+H]^+$ Calcd for C₁₇H₂₄N₃OS₃ 382.1081; Found 382.1079.

2-((4-Azidobutyl)thio)-2-(1,3-dithiolan-2-ylidene)-1-phenylethanone (2 c): 97 mg, 92%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) & 7.78-7.69 (m, 2 H), 7.44 (m, 1 H), 7.41-7.31 (m, 2 H), 3.53 (m, 2 H), 3.36 (m, 2 H), 3.06 (t, J = 6.4 Hz, 2 H), 2.45 Hz(t, J = 6.6 Hz, 2 H), 1.44 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 192.0, 176.8, 138.7, 131.1, 128.9, 127.6, 114.0, 50.8, 40.7, 35.6, 35.5, 27.6, and 26.1. HRMS (ESI-TOF) m/z: [M+ H]⁺ Calcd for C₁₅ $H_{18}N_3OS_3$ 352.0612; Found 352.0614.

2-((4-Azidobutyl)thio)-2-(1,3-dithian-2-ylidene)-1-phenylethanone (2 d): 46 mg, 42%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J=7.9 Hz, 2 H), 7.51–7.30 (m, 3 H), 3.54 (t, J = 6.5 Hz, 2 H), 3.43–3.31 (m, 2 H), 3.11 (t, J = 6.9 Hz, 2 H), 2.45 (t, J = 7.0 Hz, 2 H), 1.38 (m, 4 H), 1.26–1.17 (m, 2 H). ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 192.1, 176.5, 138.8, 131.1, 129.0, 127.6, 114.3, 51.2, 40.7, 35.9, 35.6, 28.6, 28.3, and 25.5. HRMS (ESI-TOF) m/z: $[M+H]^+$ Calcd for $C_{16}H_{20}N_3OS_3$ 366.0768; Found 366.0770.

2-((4-Azidobutyl)thio)-3,3-bis(methylthio)-1-(o-tolyl)prop-2en-1-one (2 e): 64 mg, 58%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J=7.7 Hz, 1 H), 7.42 (m, 1 H), 7.27 (m, 2 H), 3.24 (t, J=6.2 Hz, 2 H), 2.79–2.65 (m, 5 H), 2.43 (s, 3 H), 1.95 (s, 3 H), 1.72–1.62 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 193.1, 141.0, 140.7, 136.0, 133.1, 132.4, 132.3, 131.1, 125.6, 50.9, 32.9, 22.8, 26.7, 21.8, 17.9, and 16.4. HRMS (ESI-TOF) m/z: $[M+H]^+$ Calcd for C₁₆H₂₂N₃OS₃ 368.0925; Found 368.0924.

2-((4-Azidobutyl)thio)-3,3-bis(methylthio)-1-(m-tolyl)prop-2-en-1-one (2 f): 94 mg, 85%; yellow liquid. ¹H NMR

3028

© 2022 Wiley-VCH GmbH



(400 MHz, CDCl3) δ 7.78 (s, 1 H), 7.71 (d, J=7.4 Hz, 1 H), 7.38 (m, 2 H), 3.20 (t, J=6.2 Hz, 2 H), 2.61 (t, J=6.7 Hz, 2 H), 2.42 (m, 6 H), 2.08 (s, 3 H), 1.62 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl3) δ 191.2, 139.1, 138.7, 135.7, 134.6, 132.3, 129.6, 128.6, 126.8, 50.8, 32.8, 27.7, 26.6, 21.4, 18.3, and 16.2. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₂₂N₃OS₃ 368.0925; Found 368.0926.

2-((4-Azidobutyl)thio)-3,3-bis(methylthio)-1-(*p***-tolyl)prop-2-en-1-one (2 g)**: 98 mg, 89%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, *J*=8.2 Hz, 2 H), 7.29 (d, *J*=8.3 Hz, 2 H), 3.20 (t, *J*=6.2 Hz, 2 H), 2.61 (t, *J*=6.7 Hz, 2 H), 2.43 (m, 6 H), 2.10 (s, 3 H), 1.62 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 190.8, 144.8, 139.4, 133.3, 131.9, 129.6, 50.9, 32.8, 27.7, 26.7, 21.9, 18.4, and 16.2. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₂₂N₃OS₃ 368.0925; Found 368.0928.

2-((4-Azidobutyl)thio)-3,3-bis(methylthio)-1-(2-

(trifluoromethyl)phenyl)prop-2-en-1-one (2 h): 63 mg, 50%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.87–7.79 (m, 1 H), 7.70–7.65 (m, 1 H), 7.61 (m, 2 H), 3.24 (t, *J*=6.3 Hz, 2 H), 2.76–2.67 (m, 2 H), 2.48 (s, 3 H), 2.07 (s, 3 H), 1.74–1.61 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 189.7, 144.8, 137.6, 136.7, 131.7, 131.5, 130.5, 129.4 (*J*=32.5 Hz), 127.9 (*J*=5.9 Hz), 123.6 (*J*=272.2 Hz), 51.0, 33.6, 27.9, 26.7, 18.9, and 16.9. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₁₉F₃N₃OS₃ 422.0642; Found 422.0644.

2-((4-Azidobutyl)thio)-3,3-bis(methylthio)-1-(3-

(trifluoromethyl)phenyl)prop-2-en-1-one (2i): 86 mg, 68%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 8.18 (s, 1 H), 8.08 (d, J=7.8 Hz, 1 H), 7.83 (d, J=7.8 Hz, 1 H), 7.62 (t, J= 7.8 Hz, 1 H), 3.22 (m, 2 H), 2.62 (m, 2 H), 2.44 (d, J=3.4 Hz, 3 H), 2.07 (d, J=3.3 Hz, 3 H), 1.72–1.53 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 189.6, 136.9, 136.6, 135.8, 132.6, 131.5 (J=32.6 Hz), 130.0 (J=3.5 Hz), 129.5, 126.0 (J= 3.8 Hz), 122.7 (J=270.0 Hz), 50.9, 33.4, 27.8, 26.8, 18.4, and 16.3. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₁₉F₃N₃OS₃ 422.0642; Found 422.0641.

2-((4-Azidobutyl)thio)-3,3-bis(methylthio)-1-(4-

(trifluoromethyl)phenyl)prop-2-en-1-one (2 j): 83 mg, 66%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, J= 8.3 Hz, 1 H), 7.74 (d, J=8.3 Hz, 2 H), 3.23 (s, 2 H), 2.62 (t, J=6.5 Hz, 2H), 2.45 (s, 3 H), 2.08 (s, 3 H), 1.63 (td, J=6.8, 3.5 Hz, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 189.9, 138.8, 137.2, 135.6, 134.8 (J=32.5 Hz), 129.7, 125.9 (J=3.6 Hz), 123.7 (J=271.3 Hz), 50.9, 33.4, 27.8, 26.8, 18.5, and 16.3. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₁₉F₃N₃OS₃ 422.0642; Found 422.0636.

2-((4-Azidobutyl)thio)-1-(4-fluorophenyl)-3,3-bis(meth-

ylthio)prop-2-en-1-one (2 k): 80 mg, 72%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 8.07–7.90 (m, 2 H), 7.16 (t, J= 8.5 Hz, 2 H), 3.22 (t, J=6.0 Hz, 2 H), 2.61 (t, J=6.6 Hz, 2 H), 2.44 (s, 3 H), 2.10 (s, 3 H), 1.63 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 189.6, 166.1 (J=254.5 Hz), 138.2, 133.5, 132.2 (J=2.9 Hz), 132.1 (J=9.4 Hz), 116.0 (J=21.9 Hz), 50.9, 33.1, 27.7, 26.7, 18.4, and 16.2. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₅H₁₉FN₃OS₃ 372.0674; Found 372.0670.

2-((4-Azidobutyl)thio)-1-(4-chlorophenyl)-3,3-bis(meth-

ylthio)prop-2-en-1-one (21): 105 mg, 90%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.94–7.79 (m, 2 H), 7.55–7.39 (m, 2

H), 3.21 (t, J=6.2 Hz, 2 H), 2.60 (m, 2 H), 2.43 (s, 3 H), 2.09 (s, 3 H), 1.62 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 190.0, 140.3, 138.0, 134.3, 134.0, 130.8, 129.3, 50.9, 33.2, 27.8, 26.7, 18.5, and 16.3. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₅H₁₉ClN₃OS₃ 388.0379; Found 388.0380.

2-((4-Azidobutyl)thio)-1-(4-bromophenyl)-3,3-bis(meth-

ylthio)prop-2-en-1-one (2 m): 121 mg, 93%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J=8.6 Hz, 2 H), 7.61 (d, J=8.6 Hz, 2 H), 3.21 (s, 2 H), 2.59 (d, J=6.2 Hz, 2 H), 2.43 (s, 3 H), 2.08 (s, 3 H), 1.67–1.56 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 190.1, 137.8, 134.7, 134.1, 132.2, 130.9, 129.0, 50.9, 33.2, 27.8, 26.7, 18.5, and 16.3. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₅H₁₉BrN₃OS₃ 431.9874; Found 431.9868.

2-((4-Azidobutyl)thio)-3,3-bis(methylthio)-1-(naphthalen-2-

yl)prop-2-en-1-one (**2 n**): 109 mg, 90%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) $\delta \delta$ 9.07 (d, J = 8.5 Hz, 1 H), 8.10–7.97 (m, 2 H), 7.90 (d, J = 8.1 Hz, 1 H), 7.67 (m, 1 H), 7.57 (m, 1 H), 7.49 (m, 1 H), 3.19 (t, J = 6.5 Hz, 2 H), 2.74 (t, J = 7.0 Hz, 2 H), 2.44 (s, 2 H), 1.90 (s, 2 H), 1.64 (m, 4 H). ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 193.0, 141.3, 134.3, 134.1, 133.5, 133.4, 131.3, 131.2, 128.7, 128.7, 126.7, 126.2, 124.3, 50.9, 32.9, 27.8, 26.6, 18.2, and 16.4. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₉H₂₂N₃OS₃ 404.0925; Found 404.0923.

2-((4-Azidobutyl)thio)-1-(furan-2-yl)-3,3-bis(meth-

ylthio)prop-2-en-1-one (2 o): 94 mg, 91%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.60 (s, 1 H), 7.09 (d, J=3.4 Hz, 1 H), 6.51 (d, J=1.8 Hz, 1 H), 3.16 (s, 2 H), 2.60 (s, 2 H), 2.35 (s, 3 H), 2.08 (s, 3 H), 1.56 (s, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 178.8, 151.6, 147.5, 136.5, 136.1, 139.6, 112.4, 50.6, 32.8, 27.5, 26.5, 18.4, and 16.1. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₃H₁₈N₃O₂S₃ 344.0561; Found 344.0566.

2-((4-Azidobutyl)thio)-3,3-bis(methylthio)-1-(thiophen-2-

yl)prop-2-en-1-one (2 p): 101 mg, 94%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.67 (m, 2 H), 7.12 (m, 1 H), 3.19 (t, *J*=6.3 Hz, 2 H), 2.65 (t, *J*=6.8 Hz, 2 H), 2.40 (s, 3 H), 2.13 (s, 3 H), 1.60 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 183.7, 143.0, 138.2, 135.0, 134.1, 134.0, 128.3, 50.7, 33.0, 27.6, 26.6, 18.5, and 16.2. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₃H₁₈N₃OS₄ 360.0333; Found 360.0330.

2-((4-Azidobutyl)thio)-2-(1,3-dithiolan-2-ylidene)-1-(m-

tolyl)ethenone (**2 q**): 80 mg, 73%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, J=7.7 Hz, 2 H), 7.34–7.22 (m, 2 H), 3.55 (t, J=6.4 Hz, 2 H), 3.39 (t, J=6.4 Hz, 2 H), 3.10 (t, J=6.3 Hz, 2 H), 2.49 (t, J=6.4 Hz, 2 H), 2.39 (s, 3 H), 1.54– 1.38 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 192.3, 176.1, 138.7, 137.3, 131.9, 129.4, 127.5, 126.1, 114.1, 50.9, 40.7, 35.6, 35.6, 27.6, 26.1, and 21.4. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₂₀N₃OS₃ 366.0768; Found 366.0766.

2-((4-Azidobutyl)thio)-1-(2-chlorophenyl)-2-(1,3-dithiolan-2-ylidene)ethenone (2 r): 75 mg, 65%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.49–7.23 (m, 4 H), 3.64 (m, 2 H), 3.40 (m, 2 H), 3.15 (m, 2 H), 2.52 (m, 2 H), 1.50 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 191.0, 180.6, 140.0, 131.0, 130.3, 129.4, 128.4, 126.3, 114.3, 50.9, 41.3, 35.4, 35.4, 27.8, and 26.3. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₅H₁₇ClN₃OS₃ 386.0222; Found 386.0220.



2-((4-Azidobutyl)thio)-2-(1,3-dithiolan-2-ylidene)-1-(4-

fluorophenyl)ethenone (2 s): 66 mg, 59%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.88–7.72 (m, 2 H), 7.16–6.93 (m, 2 H), 3.53 (m, 2 H), 3.37 (m, 2 H), 3.09 (t, J=6.5 Hz, 2 H), 2.44 (t, J=6.7 Hz, 2 H), 1.52–1.38 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 190.5, 177.1, 164.4, (J=250.6 Hz), 134.7 (J=3.3 Hz), 131.6 (J=8.8 Hz), 114.6 (J=21.6 Hz), 113.6, 50.9, 40.7, 35.6, 35.6, 27.6, and, 26.1. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₅H₁₇FN₃OS₃ 370.0518; Found 370.0517.

2-((4-Azidobutyl)thio)-1-(4-chlorophenyl)-2-(1,3-dithiolan-2-ylidene)ethenone (2 t): 102 mg, 88%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.76–7.63 (m, 2 H), 7.42–7.29 (m, 2 H), 3.54 (dd, *J*=7.5, 5.5 Hz, 2 H), 3.37 (dd, *J*=7.5, 5.5 Hz, 2 H), 3.10 (t, *J*=6.5 Hz, 2 H), 2.44 (t, *J*=6.7 Hz, 2 H), 1.58–1.34 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 190.6, 177.9, 137.2, 137.0, 130.5, 127.9, 113.5, 50.8, 40.8, 35.7, 35.6, 27.6, and 26.1. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₅H₁₇ClN₃OS₃ 386.0222; Found 386.0221.

2-((4-Azidobutyl)thio)-1-(4-bromophenyl)-2-(1,3-dithiolan-2-ylidene)ethenone (2 u): 110 mg, 85%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.69–7.55 (m, 2 H), 7.55–7.42 (m, 2 H), 3.53 (m, 2 H), 3.35 (m, 2 H), 3.09 (t, J=6.5 Hz, 2 H), 2.43 (t, J=6.7 Hz, 2 H), 1.44 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 190.6, 178.1, 137.5, 130.8, 130.6, 125.7, 113.4, 50.8, 40.8, 35.6, 35.5, 27.6, and 26.1. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₅H₁₇BrN₃OS₃ 429.9717; Found 429.9711.

2-((4-Azidobutyl)thio)-2-(1,3-dithiolan-2-ylidene)-1-(naphthalen-2-yl)ethenone (2 v): 98 mg, 81%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 8.33 (s, 1 H), 7.96–7.79 (m, 4 H), 7.53 (m, 2 H), 3.56 (t, J=6.4 Hz, 2 H), 3.40 (t, J=6.4 Hz, 2 H), 3.01 (s, 2 H), 2.46 (d, J=6.1 Hz, 2 H), 1.44 (m, 4 H). ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 191.9, 176.5, 136.1, 134.6, 132.3, 129.9, 129.2, 127.8, 127.7, 127.3, 126.5, 125.7, 114.3, 50.9, 40.8, 35.7, 35.7, 27.7, and 26.2. HRMS (ESI-TOF) m/z:

$[M + H]^{+} Calcd for C_{19}H_{20}N_{3}OS_{3} 402.0768; Found 402.0761.$ **1-((4-Azidobutyl)thio)-1-(1,3-dithiolan-2-ylidene)propan-2-one (2w)**: 67 mg, 77%; yellow liquid. ¹H NMR (400 MHz, CDCl_{3}) δ 3.51 (m, 2 H), 3.33–3.20 (m, 4 H), 2.70 (t, *J*=7.0 Hz, 2 H), 2.43 (s, 3 H), 1.76–1.61 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl_{3}) δ 195.4, 177.0, 114.6, 51.0, 41.3, 35.5, 35.2, 28.1, 27.5, and 26.1. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₀H₁₅N₃OS₃ 290.0455; Found 290.0456.

2-((4-Azidopentyl)thio)-3,3-bis(methylthio)-1-phenylprop-2en-1-one (4 a) and 2-((5-Azidopentan-2-yl)thio)-3,3-bis(methylthio)-1-phenylprop-2-en-1-one (5 a): 85 mg, 77%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) \delta 8.03–7.85 (m, 2 H), 7.68– 7.54 (m, 1 H), 7.54–7.43 (m, 2 H), 3.69 (s, 0.45 H), 3.35 (m, 0.62 H), 3.16 (t, *J***=6.3 Hz, 0.57 H), 2.61 (t,** *J***=7.1 Hz, 1.38 H), 2.44 (t,** *J***=3.3 Hz, 3 H), 2.08 (t,** *J***=7.2 Hz, 3 H), 1.62 (qdd,** *J***=9.2, 7.3, 3.6 Hz, 2.49 H), 1.55–1.44 (m, 1.37 H), 1.25 (d,** *J***=6.8 Hz, 0.87 H), 1.18 (d,** *J***=6.5 Hz, 1.82 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) \delta 191.2, 191.1, 139.0, 137.6, 136.4, 135.8, 135.7, 133.7, 133.6, 132.5, 129.5, 129.4, 128.8, 128.7, 67.1, 57.4, 51.1, 43.2, 34.9, 34.1, 33.1, 26.1, 26.0, 21.6, 19.3, 18.5, 18.3, 16.3, 16.2. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₂₂N₃OS₃ 368.0925; Found 368.0924.**

2-((4-Azidopentyl)thio)-2-(1,3-dithiolan-2-ylidene)-1-phenylethanone (4b) and 2-((5-Azidopentan-2-yl)thio)-2-(1,3-dithiolan-2-ylidene)-1-phenylethanone (5b): 76 mg, 69%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 8.01–7.88 (m, 0.5 H), 7.75 (d, J=8.0 Hz, 1.5 H), 7.59–7.34 (m, 3 H), 5.29 (s, 0.25 H), 3.55 (m, 1.5 H), 3.48 (m, 0.5 H), 3.38 (m, 2 H), 3.22 (m, 0.5 H), 3.02 (m, 0.7 H), 2.69 (m, 0.4 H), 2.46 (m, 0.9 H), 1.65 (m, 0.8 H), 1.54–1.21 (m, 3.6 H), 1.12 (d, J=6.5 Hz, 1.2 H), 1.07 (d, J=6.8 Hz, 1.0 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 192.4, 192.1, 177.1, 176.7, 138.8, 138.9, 132.1, 131.2, 131.2, 129.3, 129.1, 128.6, 127.9, 127.7, 127.6, 114.2, 114.0, 108.4, 57.6, 51.1, 45.4, 40.8, 40.7, 35.9, 35.6, 35.6, 35.5, 34.9, 26.0, 25.7, 21.1, 19.5. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₂₀N₃OS₃ 366.0768; Found 366.0761.

2-((5-Azidopentyl)thio)-3,3-bis(methylthio)-1-phenylprop-2en-1-one (7a): 70 mg, 72%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.95 (m, 2 H), 7.61–7.56 (m, 1 H), 7.50–7.46 (m, 2 H), 3.19 (t, *J*=6.8 Hz, 2 H), 2.59 (t, *J*=7.3 Hz, 2 H), 2.43 (s, 3 H), 2.07 (s, 3 H), 1.52 (m, 4 H), 1.45–1.32 (m, 2 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 191.2, 139.5, 133.9, 133.8, 132.1, 129.5, 128.9, 51.3, 33.3, 29.1, 28.4, 25.7, 18.4, and 16.3. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₂₂N₃OS₃ 368.0925; Found 368.0926.

2-((5-Azidopentyl)thio)-3,3-bis(methylthio)-1-(*p***-tolyl)prop-2-en-1-one (7b)**: 75 mg, 65%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J*=8.2 Hz, 2 H), 7.25–7.18 (m, 2 H), 2.51 (t, *J*=7.3 Hz, 2 H), 2.38–2.32 (m, 7 H), 2.02 (s, 3 H), 1.98 (s, 3 H), 1.45 (dt, *J*=15.7, 7.9 Hz, 4 H), 1.32 (d, *J*= 6.7 Hz, 2 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 190.9, 144.8, 140.3, 133.5, 130.7, 129.6, 129.6, 34.0, 33.2, 29.1, 28.6, 27.8, 21.9, 18.4, 16.3, and 15.5. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₂₄N₃OS₃ 382.1081; Found 382.1087.

2-((5-Azidopentyl)thio)-3,3-bis(methylthio)-1-(thiophen-2-yl)prop-2-en-1-one (7 c): 68 mg, 61%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.69 (m, 2 H), 7.14 (m, 1 H), 3.21 (t, *J*= 6.8 Hz, 2 H), 2.66 (t, *J*=7.3 Hz, 2 H), 2.44 (s, 3 H), 2.16 (s, 3 H), 1.63–1.35 (m, 6 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 184.0, 143.4, 139.1, 135.1, 134.3, 133.5, 128.4, 51.3, 33.4, 29.1, 28.4, 25.8, 18.7, and 16.4. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₄H₂₀N₃OS₄ 374.0489; Found 374.0487.

(4-Azidobutyl)(2,2-diphenylvinyl)sulfane (9 a): 78 mg, 84%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.52–7.20 (m, 10 H), 6.63 (s, 1 H), 3.35 (t, *J*=6.5 Hz, 2 H), 2.85 (t, *J*=7.0 Hz, 2 H), 1.95–1.68 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.9, 139.6, 139.1, 129.8, 128.4, 128.3, 127.6, 127.1, 127.0, 125.6, 51.0, 34.3, 27.8, and 27.4. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₈H₂₀N₃S 310.1378; Found 310.1365.

(*E*)-(4-Azidobutyl)(2-phenyl-2-(*o*-tolyl)vinyl)sulfane (9 b) and (*Z*)-(4-Azidobutyl)(2-phenyl-2-(*o*-tolyl)vinyl)sulfane (9 b'): 62 mg, 64%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.27–6.98 (m, 9 H), 6.65 (s, 0.7 H), 6.10 (s, 0.2 H), 3.18 (dd, J=8.2, 4.6 Hz, 2 H), 2.82–2.58 (m, 2 H), 2.04 (s, 2.2 H), 1.94 (s, 0.7 H), 1.78–1.50 (m, 4 H).¹³C{¹H} NMR (100 MHz, CDCl₃) δ 142.8. 139.9, 139.4, 138.9, 138.8, 138.0, 136.6, 136.5, 130.4, 130.4, 130.3, 129.9, 128.8, 128.5, 128.1, 127.9, 127.5, 127.1, 126.8, 126.6, 126.2, 125.8, 125.7, 125.4, 51.0, 34.8, 33.7, 27.8, 27.8, 27.7, 27.4, 20.4, and 19.5. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₉H₂₂N₃S 324.1534; Found 324.1535.

(*E*)-(4-Azidobutyl)(2-(2-bromophenyl)-2-phenylvinyl)sulfane (9 c): 101 mg, 87%; yellow liquid. ¹H NMR (400 MHz, CDCl₃)

Adv. Synth. Catal. 2022, 364, 3023-3034

Wiley Online Library

y 3030



δ 7.45 (m, 2 H), 7.39–7.25 (m, 7 H), 6.60 (s, 1 H), 3.35 (t, J= 6.5 Hz, 2 H), 2.84 (t, J=6.9 Hz, 2 H), 1.79 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.9, 139.6, 139.1, 129.8, 128.4, 128.4, 127.6, 127.1, 127.0, 125.6, 51.1, 34.4, 27.8, and 27.5. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₁₉BrN₃S 388.0483; Found 388.0484.

(E)-(4-Azidobutyl)(2-(3,4-dimethylphenyl)-2-

phenylvinyl)sulfane (9d) and (*Z*)-(4-Azidobutyl)(2-(3,4dimethylphenyl)-2-phenylvinyl)sulfane (9d'): 78 mg, 77%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.32–6.80 (m, 8 H), 6.39 (d, *J*=3.4 Hz, 1 H), 3.17 (t, *J*=6.4 Hz, 2 H), 2.66 (t, *J*=6.9 Hz, 2 H), 2.15 (m, 6 H), 1.75–1.50 (m, 4 H).¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.1. 138.8, 138.6, 138.3, 138.2, 136.0, 135.5, 135.4, 135.0, 134.5, 129.7, 128.7, 128.6, 127.3, 127.2, 126.5, 126.2, 126.1, 125.9, 124.0, 123.6, 123.4, 50.0, 33.3, 33.3, 26.8, 26.8, 26.4, 18.9, 18.7, and 18.5. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₀H₂₄N₃S 338.1691; Found 338.1695.

(*E*)-(4-Azidobutyl)(2-phenyl-2-(*p*-tolyl)vinyl)sulfane (9 e) and (*Z*)-(4-Azidobutyl)(2-phenyl-2-(*p*-tolyl)vinyl)sulfane (9 e'): 69 mg, 71%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.31–7.09 (m, 7 H), 6.99 (d, *J*=3.3 Hz, 2 H), 6.41 (d, *J*= 3.0 Hz, 1 H), 3.17 (t, *J*=6.3 Hz, 2 H), 2.66 (td, *J*=6.9, 3.1 Hz, 2 H), 2.27 (s, 1.5 H), 2.22 (s, 1.5 H), 1.72–1.53 (m, 4 H).¹³C {¹H} NMR (100 MHz, CDCl₃) δ 142.0. 139.7, 139.1, 139.1, 139.1, 137.3, 136.7, 136.6, 129.7, 129.6, 129.1, 129.0, 128.3, 128.3, 127.5, 127.1, 127.0, 126.9, 125.2, 124.6, 51.0, 34.3, 34.3, 27.8, 27.4, 21.4, and 21.1. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₉H₂₂N₃S 324.1534; Found 324.1540.

(4-Azidobutyl)(2,2-di-*p*-tolylvinyl)sulfane (9 f): 83 mg, 82%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.09 (s, 4 H), 6.99 (q, *J*=8.3 Hz, 4 H), 6.36 (s, 1 H), 3.17 (t, *J*=6.4 Hz, 2 H), 2.66 (t, *J*=6.9 Hz, 2 H), 2.27 (s, 3 H), 2.22 (s, 3 H), 1.75–1.51 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 138.3, 138.1, 136.2, 135.7, 135.7, 128.6, 128.0, 128.0, 126.0, 123.1, 50.9, 33.3, 26.8, 26.4, 20.4, and 20.1. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₀H₂₄N₃S 338.1691; Found 338.1687.

(Z)-(4-Azidobutyl)(2-(4-fluorophenyl)-2-(4-meth-

oxyphenyl)vinyl)sulfane (9 g) and (*E*)-(4-Azidobutyl)(2-(4-fluorophenyl)-2-(4-methoxyphenyl)vinyl)sulfane (9 g'): 67 mg, 62%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.15 (m, 2.1 H), 7.09–6.90 (m, 3.2 H), 6.90–6.76 (m, 1.7 H), 6.75– 6.63 (m, 1.2 H), 6.32 (s, 0.6 H), 6.30 (s, 0.4 H), 3.70 (s, 1.3 H), 3.67 (s, 1.7 H), 3.18 (t, *J*=6.4 Hz, 2 H), 2.76–2.53 (m, 2 H), 1.69–1.53 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 161.9 (*J*=245.2 Hz), 158.9, 158.8, 138.4 (*J*=3.1 Hz), 137.8, 137.7, 135.6 (*J*=3.3 Hz), 134.5, 131.6, 131.5 (*J*=7.9 Hz), 130.9, 128.7 (*J*=7.9 Hz), 128.1, 124.6, 123.7, 115.2 (*J*=21.3 Hz), 115.0 (*J*=21.2 Hz), 113.7, 55.1, 50.9, 34.3, 27.7, and 27.4. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₉H₂₀FN₃OS 357.1311; Found 357.1310.

(4-Azidobutyl)(2,2-bis(3-(trifluorometh-

yl)phenyl)vinyl)sulfane (9 h): 96 mg, 72%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.55–7.36 (m, 6 H), 7.30 (t, J= 7.8 Hz, 1 H), 7.20 (d, J=7.8 Hz, 1 H), 6.63 (s, 1 H), 3.23 (t, J=6.4 Hz, 2 H), 2.76 (t, J=7.0 Hz, 2 H), 1.76–1.59 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 142.1, 139.6, 136.0, 133.2, 131.1 (J=32.2 Hz), 131.1 (J=31.9 Hz), 130.4, 129.4, 129.2,

129.1, 126.6 (J=3.8 Hz), 124.7 (J=3.6 Hz), 124.2 (J= 270.8 Hz), 123.9 (J=3.6 Hz), 123.5 (J=3.7 Hz), 51.0, 34.5, 27.8, and 27.6. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₀H₁₈F₆N₃S 446.1126; Found 446.1137.

(4-Azidobutyl)(2,2-bis(4-chlorophenyl)vinyl)sulfane (9i): 95 mg, 84%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.04 (m, 8 H), 6.50 (s, 1 H), 3.23 (t, J=6.4 Hz, 2 H), 2.73 (dd, J=8.3, 5.5 Hz, 2 H), 1.75–1.56 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.1, 139.6, 136.8, 131.7, 130.4, 129.3, 128.6, 127.5, 127.3, 127.1, 51.0, 34.5, 27.8, and 27.5. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₁₈Cl₂N₃S 378.0598; Found 378.0604.

(*E*)-(4-Azidobutyl)(1,2-diphenylvinyl)sulfane (9 j): 47 mg, 51%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.36 (m, 5 H), 7.12 (m, 3 H), 6.98 (m, 2 H), 6.84 (s, 1 H), 3.27 (t, *J*= 6.0 Hz, 2 H), 2.55 (t, *J*=6.7 Hz, 2 H), 1.80–1.65 (m, 4 H). ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 137.9, 137.7, 136.7, 129.7, 129.0, 128.8, 128.2, 128.1, 127.8, 126.7, 51.0, 31.2, 27.9, and 26.5. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₂₀N₃S 310.1378; Found 310.1370.

(*E*)-(4-Azidobutyl)(2-(4-fluorophenyl)-1-phenylvinyl)sulfane (9k) and (*E*)-(azidomethyl)(2-(4-fluorophenyl)-1phenylvinyl)sulfane (9k'): 60 mg, 61%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.23 (s, 4 H), 7.12–6.60 (m, 6 H), 3.14 (m, 2 H), 2.42 (m, 2 H), 1.68–1.49 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 162.5 (*J*=246.4 Hz), 161.5 (*J*= 245.5 Hz), 137.6, 137.5, 136.6 (*J*=3.7 Hz), 133.8, 132.8 (*J*= 3.5 Hz), 131.6, 131.5, 130.6, 130.5, 129.7, 129.0, 128.9, 128.3, 128.2, 128.1, 126.8, 126.7, 115.8 (*J*=21.5 Hz), 115.0 (*J*= 21.4 Hz), 51.0, 31.3, 31.2, 27.9, 27.8, 26.5, and 26.4. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₁₉FN₃S 328.1284; Found 328.1285.

(E)-(4-Azidobutyl)(2-(m-tolyl)-1-(4-(trifluorometh-

ylphenyl)vinyl)sulfane (91): 88 mg, 75%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, J=16.3 Hz, 1 H), 7.51 (s, 4 H), 7.37 (s, 1 H), 7.25 (d, J=7.9 Hz, 1 H), 6.95 (dd, J=17.0, 12.1 Hz, 2 H), 3.13 (t, J=6.4 Hz, 2 H), 2.73 (t, J=6.8 Hz, 2 H), 2.27 (s, 3H), 1.57 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.1, 138.2, 137.4, 132.4, 131.8, 129.6, 129.4 (J=33.8 Hz), 129.3, 128.7, 126.9, 126.8, 125.7 (J=3.9 Hz), 124.3 (J=270.2 Hz), 51.0, 34.8, 27.9, 26.4, and 21.2. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₀H₂₁F₃N₃S 392.1408; Found 392.1406.

(E)-(4-azidobutyl)(2-(p-tolyl)-1-(4-(trifluorometh-

yl)phenyl)vinyl)sulfane (9 m): 76 mg, 65%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, J=8.0 Hz, 2 H), 7.39 (d, J=8.0 Hz, 2 H), 6.84 (d, J=7.8 Hz, 2 H), 6.73 (d, J=7.9 Hz, 2 H), 3.15 (d, J=5.4 Hz, 2 H), 2.40 (t, J=6.1 Hz, 2 H), 2.16 (s, 3 H), 1.57 (d, J=2.8 Hz, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 142.2, 137.2, 134.7, 133.3, 130.3, 130.0 (J=32.3 Hz), 130.0, 129.1, 129.0, 125.7 (J=3.6 Hz), 124.2 (J=271.8 Hz), 51.0, 31.4, 27.8, 26.4, and 21.2. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₀H₂₁F₃N₃S 392.1408; Found 392.1411.

(*E*)-(4-Azidobutyl)(styryl)sulfane (9 n): 27 mg, 38%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.30 (m, 5 H), 6.76 (d, J=15.6 Hz, 1 H), 6.55 (d, J=15.6 Hz, 1 H), 3.35 (t, J=6.3 Hz, 2 H), 2.87 (t, J=6.7 Hz, 2 H), 1.81 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 137.0, 128.7, 127.4, 127.0, 125.5, 124.7,

Adv. Synth. Catal. 2022, 364, 3023-3034

Wiley Online Library

© 2022 Wiley-VCH GmbH



50.9, 32.1, 27.9, and 26.6. HRMS (ESI-TOF) m/z: $[M+H]^+$ Calcd for $C_{12}H_{16}N_3S$ 234.1065; Found 234.1069.

(5-Azidopentyl)(2,2-diphenylvinyl)sulfane (9 o): 75 mg, 77%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.31–7.10 (m, 10 H), 6.47 (s, 1 H), 3.16 (t, *J*=6.7 Hz, 2 H), 2.67 (t, *J*=7.3 Hz, 2 H), 1.65–1.49 (m, 4 H), 1.40 (d, *J*=6.8 Hz, 2 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 142.0, 139.6, 138.8, 129.8, 128.4, 128.3, 127.6, 127.1, 126.9, 126.0, 51.3, 34.7, 29.9, 28.5, and 25.8. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₉H₂₂N₃S 324.1534; Found 324.1542.

Typical procedure for the Synthesis of Compounds (11) – Synthesis of 11 a

A mixture of (2,2-diphenylvinyl)dimethylsulfonium trifluoromethanesulfonate (**10 a**) (117 mg, 0.3 mmol), NaN₃ (39 mg, 0.6 mmol), and 2 mL H₂O/EtOH (1/1, v/v) was stirred at 60 °C for 6 h under an air atmosphere. After **10 a** was completely consumed by TLC monitoring on silica gel, all the volatiles were evaporated under reduced pressure. The resultant residue was purified by silica gel column chromatography (eluent: petroleum ether (60–90 °C)/ethyl acetate = 30:1, v/v), affording **11 a** (60 mg, 89%) as a yellow liquid.

(2,2-Diphenylvinyl)(methyl)sulfane (11 a): 60 mg, 89%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.34–7.11 (m, 10 H), 6.47 (s, 1 H), 2.28 (s, 3 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.9, 139.6, 138.6, 129.8, 128.4, 128.4, 127.7, 127.6, 127.1, 127.0, and 18.1. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₅H₁₅S 227.0894; Found 227.0896.

n-Butyl(2,2-diphenylvinyl)sulfane (11 b): 63 mg, 78%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.39–7.04 (m, 10 H), 6.50 (s, 1 H), 2.68 (t, J=7.4 Hz, 2 H), 1.70–1.50 (m, 2 H), 1.35 (dd, J=14.9, 7.4 Hz, 2 H), 0.84 (t, J=7.4 Hz, 3 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 142.1, 139.8, 138.5, 129.9, 128.4, 128.3, 127.5, 127.1, 126.9, 126.5, 34.7, 32.6, 21.9, and 13.8. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₂₁S 269.1364; Found 269.1355.

Benzyl(2,2-diphenylvinyl)sulfane (11 c): 55 mg, 61%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.29–7.12 (m, 14 H), 7.05 (d, J=1.3 Hz, 1 H), 6.49 (s, 1 H), 3.86 (s, 2 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.9, 139.6, 139.3, 137.8, 129.8, 129.1, 128.8, 128.4, 128.3, 127.7, 127.4, 127.2, 127.0, 124.8, and 39.0. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₁H₁₉S 303.1207; Found 303.1220.

(2,2-Diphenylvinyl)(phenyl)sulfane (11 d): 37 mg, 43%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.61–6.97 (m, 15 H), 6.76 (s, 1 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.6, 141.2, 139.3, 136.6, 129.9, 129.6, 129.2, 128.5, 128.4, 127.9, 127.4, 127.3, 126.9, and 124.2. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₀H₁₇S 289.1051; Found 289.1057.

Synthesis of 3,3-bis(methylthio)-1-phenyl-2-((4-(4-phenyl-1H-1,2,3-triazol -1-yl)butyl)thio)prop-2-en-1-one (13)

A mixture of 2-((4-azidobutyl)thio)-3,3-bis(methylthio) -1phenylprop-2-en-1-one (**2 a**) (106 mg, 0.3 mmol), phenylacetylene (61 mg, 0.6 mmol), and CuBr (4.3 mg, 0.03 mmol) in 2 mL 1,4-dioxane was stirred at 80 °C for 12 h. After **2a** was completely consumed by TLC monitoring on silica gel, all the volatiles were evaporated under reduced pressure. The resultant residue was purified by silica gel column chromatography (eluent: petroleum ether (60–90 °C)/ethyl acetate = 30:1, v/v), affording **13** (124 mg, 91%) as a yellow solid.

3,3-Bis(methylthio)-1-phenyl-2-((4-(4-phenyl-1H-1,2,3-tria-

zol-1-yl)butyl)thio)prop-2-en-1-one (13): 124 mg, 91%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.97–7.89 (m, 2 H), 7.81 (m, 3 H), 7.56 (d, *J*=7.4 Hz, 1 H), 7.44 (dt, *J*=15.1, 7.8 Hz, 4 H), 7.33 (d, *J*=7.4 Hz, 1 H), 4.33 (t, *J*=7.1 Hz, 2 H), 2.64 (t, *J*=7.1 Hz, 2 H), 2.41 (s, 3 H), 2.08–1.93 (m, 5 H), 1.66–1.54 (m, 2 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 191.1, 147.7, 138.0, 135.7, 133.8, 130.7, 129.4, 128.8, 128.1, 125.7, 119.6, 49.7, 32.8, 29.0, 26.5, 18.3, and 16.2. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₃H₂₆N₃OS₃ 456.1238; Found 456.1231.

Synthesis of 1-(4-((3-(methylthio)-5-phenyl-1H-pyrazol-4-yl)thio)butyl) -4-phenyl-1H-1,2,3-triazole (14)

A mixture of 3,3-bis(methylthio)-1-phenyl-2-((4-(4-phenyl-1*H*-1,2,3-triazol-1-yl)butyl)thio)prop-2-en-1-one (13) (137 mg, 0.3 mmol), and hydrazine hydrate (150 mg, 3 mmol) in 2 mL EtOH was stirred at 80 °C for 12 h. After 13 was completely consumed by TLC monitoring on silica gel, all the volatiles were evaporated under reduced pressure. The resultant residue was purified by silica gel column chromatography (eluent: petroleum ether (60–90 °C)/ethyl acetate = 30:1, v/v), affording 14 (51 mg, 40%) as a yellow liquid.

1-(4-((3-(Methylthio)-5-phenyl-1H-pyrazol-4-yl)thio)butyl)-

4-phenyl-1*H***-1,2,3-triazole (14)**: 57 mg, 40%; yellow solid, m.p.: 96–97 °C. ¹H NMR (400 MHz, d₆-DMSO) δ 13.43 (s, 1 H), 8.43 (s, 1 H), 7.84 (d, *J*=7.6 Hz, 4 H), 7.55–7.38 (m, 5 H), 7.33 (d, *J*=7.2 Hz, 1 H), 4.24 (t, *J*=6.6 Hz, 2 H), 2.61 (t, *J*= 6.7 Hz, 2 H), 2.49 (s, 3 H), 1.91–1.71 (m, 2 H), 1.44–1.29 (m, 2 H). ¹³C{¹H} NMR (100 MHz, d₆-DMSO) δ 152.5, 146.7, 146.1, 131.3, 129.3, 129.1, 128.2, 127.9, 125.6, 121.6, 104.4, 49.5, 35.2, 28.9, 26.1, and 14.1. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₂H₂₄N₃S₂ 422.1473; Found 422.1464.

Synthesis of 3,3-bis(methylthio)-1-phenyl-2-((4-(5-phenyl-2H-tetrazol-2-yl) butyl)thio)prop-2-en-1-one (15)

A mixture of 2-((4-azidobutyl)thio)-3,3-bis(methylthio)-1- phenylprop-2-en-1-one (**2 a**) (106 mg, 0.3 mmol) and benzoyl cyanide (79 mg, 0.6 mmol), in 2 mL MeCN was stirred at 130 °C for 36 h. After **2 a** was completely consumed by TLC monitoring on silica gel, all the volatiles were evaporated under reduced pressure. The resultant residue was purified by silica gel column chromatography (eluent: petroleum ether (60– 90 °C)/ethyl acetate = 30:1, v/v), affording **15** (70 mg, 51%) as a yellow liquid.

3,3-Bis(methylthio)-1-phenyl-2-((4-(5-phenyl-2*H***-tetrazol-2yl)butyl)thio)prop-2-en-1-one (15): 70 mg, 51%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) & 8.51–8.35 (m, 2 H), 7.89 (m, 2 H), 7.78–7.65 (m, 1 H), 7.61–7.51 (m, 3 H), 7.46 (m, 2**

Adv. Synth. Catal. 2022, 364, 3023-3034

Wiley Online Library 30

3032



H), 4.68 (t, J=7.3 Hz, 2 H), 2.65 (t, J=7.1 Hz, 2 H), 2.41 (s, 3 H), 2.11–1.94 (m, 5 H), 1.70–1.55 (m, 3 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 191.1, 181.6, 149.5, 138.1, 135.8, 135.3, 135.1, 134.1, 133.8, 131.2, 129.5, 129.0, 128.9, 49.4, 32.8, 28.8, 26.4, 18.5, and 16.3. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₃H₂₅N₄O₂S₃ 485.1140; Found 485.1133.

Synthesis of 4-((4-azidobutyl)thio)-3-(methylthio)-5-phenyl-1H-pyrazole (16)

A mixture of 2-((4-azidobutyl)thio)-3,3-bis(methylthio)-1- phenylprop-2-en-1-one (2a) (106 mg, 0.3 mmol), and hydrazine hydrate (150 mg, 3 mmol) in 2 mL EtOH was stirred at 80 °C for 12 h. After 2a was completely consumed by TLC monitoring on silica gel, all the volatiles were evaporated under reduced pressure. The resultant residue was purified by silica gel column chromatography (eluent: petroleum ether (60– 90 °C)/ethyl acetate = 30:1, v/v), affording 16 (83 mg, 87%) as a yellow liquid.

4-((4-Azidobutyl)thio)-3-(methylthio)-5-phenyl-1*H***-pyrazole (16)**: 83 mg, 87%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.94–7.65 (m, 2 H), 7.61–7.27 (m, 3 H), 3.03 (t, *J*=6.9 Hz, 2 H), 2.56 (t, *J*=6.8 Hz, 2 H), 2.42 (s, 3 H), 1.52 (m, 2 H), 1.40 (m, 2 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.8, 148.0, 129.3, 129.0, 128.7, 127.6, 106.7, 50.8, 35.4, 27.5, 26.1, and 15.0. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₄H₁₈N₅S₂ 320.1004; Found 320.1006.

Synthesis of 4-((4-azidobutyl)thio)-3-(methylthio)-1,5-diphenyl-1H-pyrazole (17)

A mixture of 2-((4-azidobutyl)thio)-3,3-bis(methylthio)-1- phenylprop-2-en-1-one (**2a**) (106 mg, 0.3 mmol) and phenylhydrazine (65 mg, 0.6 mmol) in 2 mL EtOH was stirred at 80 °C for 24 h. After **2a** was completely consumed by TLC monitoring on silica gel, all the volatiles were evaporated under reduced pressure. The resultant residue was purified by silica gel column chromatography (eluent: petroleum ether (60–90 °C)/ethyl acetate = 30:1, v/v), affording **17** (85 mg, 72%) as a yellow solid.

4-((4-Azidobutyl)thio)-3-(methylthio)-1,5-diphenyl-1H-

pyrazole (17): 85 mg, 72%; yellow solid, m.p.: 105–106 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.37 (m, 3 H), 7.29 (m, 7 H), 3.03 (t, *J*=6.6 Hz, 2 H), 2.67 (s, 3 H), 2.61 (t, *J*=6.5 Hz, 2 H), 1.55–1.34 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 153.1, 146.9, 139.7, 130.1, 129.2, 128.8, 128.7, 128.2, 127.1, 124.5, 109.3, 50.8, 35.1, 27.2, 26.1, and 14.1. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₀H₂₂N₅S₂ 396.1317; Found 396.1314.

Synthesis of 4-((4-azidobutyl)thio)-3-(methylthio)-5-phenylisoxazole (18)

A mixture of 2-((4-azidobutyl)thio)-3,3-bis(methylthio)-1- phenylprop-2-en-1-one (**2a**) (106 mg, 0.3 mmol), hydroxylamine hydrochloride (209 mg, 3 mmol), and K_2CO_3 (415 mg, 3 mmol) in 2 mL EtOH was stirred at 80 °C for 12 h. After **2a** was completely consumed by TLC monitoring on silica gel, all the volatiles were evaporated under reduced pressure. The resultant residue was purified by silica gel column chromatography (eluent: petroleum ether (60–90 °C)/ethyl acetate = 30:1, v/v), affording **18** (78 mg, 81%) as a yellow liquid.

4-((4-Azidobutyl)thio)-3-(methylthio)-5-phenylisoxazole

(18): 78 mg, 81%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 8.27–8.03 (m, 2 H), 7.63–7.42 (m, 3 H), 3.13 (t, J=6.7 Hz, 2 H), 2.72 (t, J=6.9 Hz, 2 H), 2.63 (s, 3 H), 1.67–1.51 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 169.8, 165.9, 130.8, 128.9, 127.3, 127.3, 104.4, 50.9, 34.9, 27.7, 26.5, and 13.3. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₄H₁₇N₄OS₂ 321.0844; Found 321.0842.

Synthesis of 5-((4-azidobutyl)thio)-4-(methylthio)-6-phenylpyrimidin-2-amine (19)

A mixture of 2-((4-azidobutyl)thio)-3,3-bis(methylthio)-1- phenylprop-2-en-1-one (**2a**) (106 mg, 0.3 mmol), guanidine nitrate (73 mg, 0.6 mmol), and K_2CO_3 (83 mg, 0.6 mmol) in 2 mL MeCN was stirred at 100 °C for 36 h. After **2a** was completely consumed by TLC monitoring on silica gel, all the volatiles were evaporated under reduced pressure. The resultant residue was purified by silica gel column chromatography (eluent: petroleum ether (60–90 °C)/ethyl acetate = 30:1, v/v), affording **19** (66 mg, 63%) as a yellow liquid.

5-((4-Azidobutyl)thio)-4-(methylthio)-6-phenylpyrimidin-2amine (19): 66 mg, 63%; yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.66–7.55 (m, 2 H), 7.49–7.38 (m, 3 H), 5.25 (s, 2 H), 3.02 (t, *J*=6.6 Hz, 2 H), 2.55–2.35 (m, 5 H), 1.44–1.22 (m, 4 H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 178.1, 169.1, 160.9, 138.5, 129.4, 129.2, 127.9, 112.4, 50.9, 35.2, 27.6, 26.1, and 14.3. HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₅H₁₉N₆S₂ 347.1113; Found 347.1119.

Acknowledgements

We are grateful to the National Natural Science Foundation of China (22171261 and 21871253) for support of this research.

References

- M. Bodenteich, B. Griengl, *Tetrahedron Lett.* 1987, 28, 5311–5312.
- [2] X. Lin, C. X. Liang, L. J. Zou, Y. C. Yin, J. Y. Wang, D. D. Chen, W. S. Lan, *Eur. J. Med. Chem.* **2021**, *214*, 113233–113254.
- [3] L. B. Niu, C. Y. Jiang, Y. W. Liang, D. D. Liu, F. X. Bu, R. Y. Shi, H. Chen, A. D. Chowdhury, A. W. Lei, J. Am. Chem. Soc. 2020, 142, 17693–17702.
- [4] S. Lang, J. A. Murphy, Chem. Soc. Rev. 2006, 35, 146– 156.
- [5] a) J. Fu, G. Zanoni, E. A. Anderson, X. H. Bi, *Chem. Soc. Rev.* 2017, 46, 7208–7228; b) P. Sivaguru, Y. Q. Ning, X. H. Bi, *Chem. Rev.* 2021, 121, 4253–4307.
- [6] a) P. Thirumurugan, D. Matosiuk, K. Jozwiak, *Chem. Rev.* 2013, *113*, 4905–4979; b) G. Meng, T. Guo, T. Ma, J. Zhang, Y. Shen, K. B. Sharpless, J. Dong, *Nature* 2019, *574*, 86–89.



- [7] a) J. E. Moses, A. D. Moorhouse, *Chem. Soc. Rev.* 2007, 36, 1249–1262; b) H. C. Kolb, M. G. Finn, K. B. Sharpless, *Angew. Chem. Int. Ed.* 2001, 40, 2004–2021; *Angew. Chem.* 2001, 113, 2056–2075.
- [8] S. S. van Berkel, M. B. van Eldijk, J. C. M. van Hest, Angew. Chem. Int. Ed. 2011, 50, 8806–8827; Angew. Chem. 2011, 123, 8968–8989.
- [9] a) Z. Zhang, B. Huang, G. Qiao, L. Zhu, F. Xiao, F. Chen, B. Fu, Z. Zhang, Angew. Chem. Int. Ed. 2017, 56, 4320–4323; Angew. Chem. 2017, 129, 4384–4387; b) C. Ollivier, P. Renaud, J. Am. Chem. Soc. 2001, 123, 4717–4727; c) C. Liu, X. Q. Wang, Z. D. Li, L. Cui, C. Z. Li, J. Am. Chem. Soc. 2015, 137, 9820–9823; d) D. C. Marcote, R. Street-Jeakings, E. Dauncey, J. J. Douglas, A. Ruffoni, D. Leonori, Org. Biomol. Chem. 2019, 17, 1839–1842; e) P. T. G. Rabet, G. Fumagalli, S. Boyd, M. F. Greaney, Org. Lett. 2016, 18, 1646–1649; f) Y. X. Wang, G.-X. Li, G. H. Yang, G. Hea, G. Chen, Chem. Sci. 2016, 7, 2679–2683; g) X. F. Zhang, H. D. Yang, P. P. Tang, Org. Lett. 2015, 17, 5828–5831; h) S.-E. Suh, S.-J. Chen, M. Mandal, I. A. Guzei, C. J. Cramer, S. S. Stahl, J. Am. Chem. Soc. 2020, 142, 11388–11393.
- [10] a) K. Wu, Y. Liang, N. Jiao, *Molecules* 2016, 21, 352–373; b) X. Huang, J. T. Groves, *ACS Catal.* 2016, 6, 751–759; c) H. Hayashi, A. Kaga, S. Chiba, *J. Org. Chem.* 2017, 82, 11981–11989.
- [11] a) E. L. Eliel, R. O. Hutchins, R. Mebane, R. L. Willer, J. Org. Chem. 1976, 41, 1052–1057; b) M. H. Benn, V. K. Singh, Can. J. Chem. 1986, 64, 940–942; c) D.-V. Vo, V.-D. Truong, T.-D. Tran, V.-T.-N. Do, N.-T.-A. Pham, K.-M. Thai, Lett. Org. Chem. 2015, 13, 7–10; d) N. Wang, Y. M. Jia, H. M. Qin, Z.-X. Jiang, Z. G. Yang, Org. Lett. 2020, 22, 7378–7382; e) C. M. Lopez-Alled, F. J. O. Martin, K.-Y. Chen, G. Kociok-Kohn, T. D. James, J. Wenk, S. E. Lewis, Tetrahedron 2020, 76, 131700–131711.
- [12] a) D. Kaiser, I. Klose, R. Oost, J. Neuhaus, N. Maulide, *Chem. Rev.* 2019, *119*, 8701–8780; b) J. Lou, Q. N. Wang, P. Wu, H. M. Wang, Y.-G. Zhou, Z. K. Yu, *Chem. Soc. Rev.* 2020, *49*, 4307–4359; c) M. Mondal, S. Chen, N. J. Kerrigan, *Molecules* 2018, *23*, 738–766.
- [13] a) A. Peter, G. J. Perry, D. J. Procter, Adv. Synth. Catal.
 2020, 362, 2135–2142; b) H. Yorimitsu, Chem. Rec.
 2017, 17, 1156–1167; c) K. Nogi, H. Yorimitsu, Chem. Commun. 2017, 53, 4055–4065; d) P. Cowper, Y. Jin, M. D. Turton, G. Kociok-Köhn, S. E. Lewis, Angew. Chem. Int. Ed. 2016, 55, 2564–2568; Angew. Chem.
 2016, 128, 2610–2614; e) F. Ye, F. Berger, H. Jia, J.

Ford, A. Wortman, J. Börgel, C. Genicot, T. Ritter, Angew. Chem. Int. Ed. 2019, 58, 14615–14619; Angew. Chem. 2019, 131, 14757–14761; f) M. H. Aukland, M. Šiaučiulis, A. West, G. J. P. Perry, D. J. Procter, Nat. Catal. 2020, 3, 163–169; g) J. Srogl, G. D. Allred, L. S. Liebeskind, J. Am. Chem. Soc. 1997, 119, 12376–12377.

- [14] a) Z.-Y. Tian, C.-P. Zhang, Chem. Commun. 2019, 55, 11936–11939; b) P. S. Engl, A. P. Haring, F. Berger, G. Berger, A. Perez-Bitria, T. Ritter, J. Am. Chem. Soc. 2019, 141, 13346–13351; c) H. Minami, S. Otsuka, K. Nogi, H. Yorimitsu, ACS Catal. 2018, 8, 579–583; d) F. Berger, M. B. Plutschack, J. Riegger, W. W. Yu, S. Speicher, M. Ho, N. Frank, T. Ritter, Nature 2019, 567, 223–228; e) Y. C. Wu, Y.-H. Huang, X.-Y. Chen, P. Wang, Org. Lett. 2020, 22, 6657–6661.
- [15] a) M. H. Aukland, F. J. T. Talbot, J. A. Fernandez-Salas, M. Ball, A. P. Pulis, D. J. Procter, Angew. Chem. Int. Ed. 2018, 57, 9785-9789; Angew. Chem. 2018, 130, 9933-9937; b) J. T. Chen, J. K. Li, M. B. Plutschack, F. Berger, T. Ritter, Angew. Chem. Int. Ed. 2020, 59, 5616-5620; Angew. Chem. 2020, 132, 5665-5669; c) M. Šiaučiulis, N. Ahlsten, A. P. Pulis, D. J. Procter, Angew. Chem. Int. Ed. 2018, 57, 5759-5764; Angew. Chem. 2018, 130, 5861-5866; d) Y.-L. Zhang, L. Yang, J. Wu, C. Y. Zhu, P. Wang, Org. Lett. 2020, 22, 7768-7772; e) D. J. Wang, K. Targos, Z. K. Wickens, J. Am, Chem. Soc. Rev. 2021, 143, 21503-21510; f) M.-S. Liu, H.-W. Du, W. Shu, Chem. Sci. 2022, 13, 1003-1008; g) L.-H. Zou, B. Liu, C. Wang, Z. Y. Shao, J. Q. Zhou, A. D. Shao, J. Wen, Org. Chem. Front. 2022, 9, 3231-3236; h) H. Yamanaka, J. Matsuo, A. Kawana, T. Mukaiyama, Arkivoc 2004, 2004, 42-65; i) J. V. Matlock, S. P. Fritz, S. A. Harrison, D. M. Coe, E. M. McGarrigle, V. K. Aggarwal, J. Org. Chem. 2014, 79, 10226-10239; j) R. Maeda, K. Ooyama, R. Anno, M. Shiosaki, T. Azema, T. Hanamoto, Org. Lett. 2010, 12, 2548-2550.
- [16] a) H. F. Yu, Z. K. Yu, Angew. Chem. Int. Ed. 2009, 48, 2929–2933; Angew. Chem. 2009, 121, 2973–2977;
 b) H. F. Yu, W. W. Jin, C. L. Sun, J. P. Chen, W. M. Du, S. B. He, Z. K. Yu, Angew. Chem. Int. Ed. 2010, 49, 5792–5797; Angew. Chem. 2010, 122, 5928–5933;
 c) Q. N. Wang, X. G. Yang, P. Wu, Z. K. Yu, Org. Lett. 2017, 19, 6248–6251.
- [17] Y. He, Z. L. Huang, J. Ma, F. Huang, J. Lin, H. M. Wang, B.-H. Xu, Y.-G. Zhou, Z. K. Yu, Org. Lett. 2021, 23, 6110–6114.
- [18] J. Schmitt, S. L. Huang, E. Goodfellow, C. Williams, B. J. Jean-Claude, J. Med. Chem. 2020, 63, 5752–5762.